MedTrace Logo

Smoking Cessation and Functional CT Assessment

NCT03382106 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2025-02-14

No results posted yet for this study

Summary

The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema.

Conditions

  • Emphysema

Interventions

DRUG

Sildenafil 20 MG

Sildenafil, 20mg three times daily for 3 month period.

DRUG

Placebo Oral Tablet

Placebo manufactured to look like Sildenafil 20 MG

DIAGNOSTIC_TEST

Pulse wave velocity

Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.

DIAGNOSTIC_TEST

Carotid artery compliance and stiffness

An echocardiogram is done by using a probe placed on the skin.

DIAGNOSTIC_TEST

Pressure wave reflection

Carotid pulse measurement taken using a tonometer probe

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Eric A. Hoffman

    lead OTHER

Principal Investigators

  • Eric Hoffman, PhD · Professor

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-19
Primary Completion
2024-09-24
Completion
2024-09-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03382106 on ClinicalTrials.gov